GFAP and cerebral amyloid angiopathy: To investigate the effects of targeted knockdown of transforming growth factor-beta receptor II (TGF-PR2) in cerebral amyloid angiopathy (CAA) mice, we conducted immunohistochemical analyses focusing on TGF-βR2 and glial fibrillary acidic protein (GFAP) expressions.